BRAF and melanoma: We tested our hypothesis using T24 cell line and treated it with vemurafenib as Braf is a more upstream component of the Braf/MEK/ERK pathway, while this molecule has been shown to be an effective treatment for melanoma patients in a Phase III study [27].